Full text biomedical articles
Spironolactone is an antagonist of NRG1âERBB4 signaling and schizophreniaârelevant endophenotypes in miceMichael C Wehr, Wilko Hinrichs, Magdalena M Brzózka, Tilmann Unterbarnscheidt, Alexander Herholt, Jan P Wintgens, Sergi Papiol, Maria Clara SotoâBernardini, Mykola Kravchenko, Mingyue Zhang, KlausâArmin Nave, Sven P Wichert, Peter Falkai, Weiqi Zhang, Markus H Schwab, Moritz J Rossner
EMBO Mol Med. 2017 Oct; 9(10): 1448â1462. Published online 2017 Jul 25. doi:Â 10.15252/emmm.201707691
Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and PerspectivesAntonis A Manolis, Theodora A Manolis, Helen Melita, Antonis S Manolis
Vasc Health Risk Manag. 2019; 15: 571â579. Published online 2019 Dec 30. doi:Â 10.2147/VHRM.S210150
Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic ReviewAlison M. Layton, E. Anne Eady, Heather Whitehouse, James Q. Del Rosso, Zbys Fedorowicz, Esther J. van Zuuren
Am J Clin Dermatol. 2017; 18(2): 169â191. Published online 2017 Feb 2. doi:Â 10.1007/s40257-016-0245-x
The mineralocorticoid receptor antagonist spironolactone reduces alcohol self- administration in female and male ratsViren H. Makhijani, Kalynn Van Voorhies, Joyce Besheer
Pharmacol Biochem Behav. Author manuscript; available in PMC 2019 Dec 1.
Published in final edited form as: Pharmacol Biochem Behav. 2018 Dec; 175: 10â18. Published online 2018 Aug 29. doi:Â 10.1016/j.pbb.2018.07.011
Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record dataMegan Shuey, Bradley Perkins, Hui Nian, Chang Yu, James M Luther, Nancy Brown
BMJ Open. 2020; 10(5): e033100. Published online 2020 May 26. doi:Â 10.1136/bmjopen-2019-033100
Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug SpironolactoneMiranda E. Good, Yu-Hsin Chiu, Ivan K. H. Poon, Chris Medina, Joshua T. Butcher, Suresh K. Mendu, Leon J. DeLalio, Alexander W. Lohman, Norbert Leitinger, Eugene Barrett, Ulrike M. Lorenz, Bimal N. Desai, Iris Z. Jaffe, Douglas A. Bayliss, Brant E. Isakson, Kodi S. Ravichandran
Circ Res. Author manuscript; available in PMC 2019 Feb 16.
Published in final edited form as: Circ Res. 2018 Feb 16; 122(4): 606â615. Published online 2017 Dec 13. doi:Â 10.1161/CIRCRESAHA.117.312380
Spironolactone metabolite concentrations in decompensated heart failure: Insights from the ATHENA-HF trial.Simon de Denus, Grégoire Leclair, Marie-Pierre Dubé, Isabelle St-Jean, Yassamin Feroz Zada, Essaïd Oussaïd, Martin Jutras, Michael M. Givertz, Robert J. Mentz, W. H. Wilson Tang, João P Ferreira, Jean Rouleau, Javed Butler, Andreas P. Kalogeropoulos
Eur J Heart Fail. Author manuscript; available in PMC 2021 Aug 1.
Published in final edited form as: Eur J Heart Fail. 2020 Aug; 22(8): 1451â1461. Published online 2020 Apr 1. doi:Â 10.1002/ejhf.1802
Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat modelChun-Cheng Wang, An-Sheng Lee, Shu-Hui Liu, Kuan-Cheng Chang, Ming-Yi Shen, Chiz-Tzung Chang
BMC Nephrol. 2019; 20: 351. Published online 2019 Sep 6. doi:Â 10.1186/s12882-019-1534-4
Interventions for hirsutism (excluding laser and photoepilation therapy alone)Esther J van Zuuren, Zbys Fedorowicz, Ben Carter, Nikolaos Pandis
Cochrane Database Syst Rev. 2015 Apr; 2015(4): CD010334. Published online 2015 Apr 28. doi:Â 10.1002/14651858.CD010334.pub2
Spironolactone use and risk of incident cancers: a retrospective, matched cohort studyIsla S. Mackenzie, Steven V. Morant, Li Wei, Alastair M. Thompson, Thomas M. MacDonald
Br J Clin Pharmacol. 2017 Mar; 83(3): 653â663. Published online 2016 Nov 12. doi:Â 10.1111/bcp.13152
Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysisCong Chen, Xue-Ying Zhu, Dong Li, Qian Lin, Kun Zhou
Medicine (Baltimore) 2020 Aug 21; 99(34): e21694. Published online 2020 Aug 21. doi:Â 10.1097/MD.0000000000021694
National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011Wenchi Guan, Karthik Murugiah, Nicholas Downing, Jing Li, Qing Wang, Joseph S Ross, Nihar R Desai, Frederick A Masoudi, John A Spertus, Xi Li, Harlan M Krumholz, Lixin Jiang, for the China PEACE Collaborative Group
J Am Heart Assoc. 2015 Jun; 4(6): e001718. Published online 2015 Jun 12. doi:Â 10.1161/JAHA.114.001718
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytesDan Dong, Ting-ting Fan, Ying-shi Ji, Jin-yu Yu, Shan Wu, Li Zhang
Int Urol Nephrol. 2019; 51(4): 755â764. Published online 2019 Feb 8. doi:Â 10.1007/s11255-019-02074-9
In Vitro and In Vivo Studies of Spironolactone as an Antischistosomal Drug Capable of Clinical RepurposingRafael A. Guerra, Marcos P. Silva, Tais C. Silva, Maria C. Salvadori, Fernanda S. Teixeira, Rosimeire N. de Oliveira, Jefferson A. Rocha, Pedro L. S. Pinto, Josué de Moraes
Antimicrob Agents Chemother. 2019 Mar; 63(3): e01722-18. Prepublished online 2018 Dec 17. Published online 2019 Feb 26. doi:Â 10.1128/AAC.01722-18
Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive ratCatherine J. Leader, Darren J. Kelly, Ivan A. Sammut, Gerard T. Wilkins, Robert J. Walker
Physiol Rep. 2020 May; 8(10): e14448. Published online 2020 May 22. doi:Â 10.14814/phy2.14448
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with HyperkalemiaMark Bounthavong, Javed Butler, Chantal M. Dolan, Jeffrey D. Dunn, Kathryn A. Fisher, Nina Oestreicher, Bertram Pitt, Paul J. Hauptman, David L. Veenstra
Pharmacoeconomics. 2018; 36(12): 1463â1473. Published online 2018 Sep 8. doi:Â 10.1007/s40273-018-0709-3
Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection FractionEssraa Bayoumi, Phillip H. Lam, Daniel J. Dooley, Steven Singh, Charles Faselis, Charity J. Morgan, Samir Patel, Helen M. Sheriff, Selma F. Mohammed, Carlos E. Palant, Bertram Pitt, Gregg C. Fonarow, Ali Ahmed
Am J Med. Author manuscript; available in PMC 2020 Jan 1.
Published in final edited form as: Am J Med. 2019 Jan; 132(1): 71â80.e1. Published online 2018 Sep 19. doi:Â 10.1016/j.amjmed.2018.09.011
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degenerationMin Zhao, Irmela Mantel, Emmanuelle Gelize, Xinxin Li, Xiaoyue Xie, Alejandro Arboleda, Marie Seminel, Rinath Levy-Boukris, Marilyn Dernigoghossian, Andrea Prunotto, Charlotte Andrieu-Soler, Carlo Rivolta, Jérémie Canonica, Marie-Christine Naud, Sebastian Lechner, Nicolette Farman, Irene Bravo-Osuna, Rocio Herrero-Vanrell, Frederic Jaisser, Francine Behar-Cohen
Nat Commun. 2019; 10: 369. Published online 2019 Jan 21. doi:Â 10.1038/s41467-018-08125-6
Molecular evolution of the switch for progesterone and spironolactone from mineralocorticoid receptor agonist to antagonistPeter J. Fuller, Yi-Zhou Yao, Ruitao Jin, Sitong He, Beatriz MartÃn-Fernández, Morag J. Young, Brian J. Smith
Proc Natl Acad Sci U S A. 2019 Sep 10; 116(37): 18578â18583. Published online 2019 Aug 22. doi:Â 10.1073/pnas.1903172116
Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigsWennan Li, Xingjuan Chen, Ashley M. Riley, S. Christopher Hiett, Constance J. Temm, Eleni Beli, Xin Long, Saikat Chakraborty, Mouhamad Alloosh, Fletcher A. White, Maria B. Grant, Michael Sturek, Alexander G. Obukhov
Basic Res Cardiol. 2017; 112(5): 54. Published online 2017 Jul 29. doi:Â 10.1007/s00395-017-0643-0
|